Hemin preconditioning upregulates heme oxygenase-1 in deceased donor renal transplant recipients: A randomized, controlled, phase IIB Trial

Transplantation

Volumn 100, Issue 1, 2016, Pages 176-183

  Thomas, Rachel A B ^a   Czopek, Alicja ^a   Bellamy, Christopher O C ^b   McNally, Stephen J ^a,c   Kluth, David C ^a   Marson, Lorna P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEME ARGINATE; HEME OXYGENASE 1; KIDNEY INJURY MOLECULE 1; MESSENGER RNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; ARGININE; BIOLOGICAL MARKER; HEME; HMOX1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CADAVER KIDNEY; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DRUG SAFETY; DRUG TOLERABILITY; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC PRECONDITIONING; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MACROPHAGE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; UPREGULATION; ADVERSE EFFECTS; BIOPSY; BIOSYNTHESIS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYME INDUCTION; ENZYMOLOGY; GENETICS; GRAFT RECIPIENT; KIDNEY; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; SCOTLAND; TIME FACTOR; TREATMENT OUTCOME; URINE; YOUNG ADULT;

ADULT; AGED; ARGININE; BIOMARKERS; BIOPSY; DRUG ADMINISTRATION SCHEDULE; ENZYME INDUCTION; FEMALE; HEME; HEME OXYGENASE-1; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MALE; MIDDLE AGED; RNA, MESSENGER; SCOTLAND; TIME FACTORS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84952334326     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000770     Document Type: Article

References (30)

1. Oniscu GC, Brown H, Forsythe JL. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol. 2005; 16(6):1859-1865.
2. Chatauret N, Badet L, Barrou B, et al. Ischemia-reperfusion: From cell biology to acute kidney injury. Prog Urol. 2014;24(Suppl 1):S4-S12.
3. Yarlagadda SG, Coca SG, Formica RN Jr, et al. Association between delayed graft function and allograft and patient survival: A systematic review and meta-Analysis. Nephrol Dial Transplant. 2009;24(3):1039-1047.
4. Selzner N, Boehnert M, Selzner M. Preconditioning, postconditioning, and remote conditioning in solid organ transplantation: basicmechanisms and translational applications. Transplant Rev (Orlando). 2012;26(2):115-124.
5. Ferenbach DA, Kluth DC, Hughes J. Hemeoxygenase-1 and renal ischaemia-reperfusion injury. Nephron Exp Nephrol. 2010;115(3):e33-e37.
6. Kirkby KA, Adin CA. Products of heme oxygenase and their potential therapeutic applications. Am J Physiol Renal Physiol. 2006;290(3): F563-F571.
7. Nath KA. Heme oxygenase-1: A provenance for cytoprotective pathways in the kidney and other tissues. Kidney Int. 2006;70(3):432-443.
8. Roach JP, Moore EE, Partrick DA, et al. Heme oxygenase-1 induction in macrophages by a hemoglobin-based oxygen carrier reduces endotoxinstimulated cytokine secretion. Shock. 2009;31(3):251-257.
9. Lee S, Huen S, Nishio H, et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol. 2011;22(2): 317-326.
10. Gueler F, Park JK, Rong S, et al. Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol. 2007;170(4):1192-1199.
11. Ferenbach DA, Ramdas V, Spencer N, et al. Macrophages expressing heme oxygenase-1 improve renal function in ischemia/reperfusion injury. Mol Ther. 2010;18(9):1706-1713.
12. Ferenbach DA, Nkejabega NC, McKay J, et al. The induction of macrophage hemeoxygenase-1 is protective during acute kidney injury in aging mice. Kidney Int. 2011;79(9):966-976.
13. Bharucha AE, Kulkarni A, Choi KM, et al. First-in-human study demonstrating pharmacological activation of heme oxygenase-1 in humans.Clin Pharmacol Ther. 2010;87(2):187-190.
14. Doberer D, Haschemi A, AndreasM, et al.Haem arginate infusion stimulates haem oxygenase-1 expression in healthy subjects. Br J Pharmacol. 2010;161(8):1751-1762.
15. de Almeida MC, Silva AC, Barral A, et al. A simple method for human peripheral blood monocyte isolation. Mem Inst Oswaldo Cruz. 2000;95 (2):221-223.
16. Hill-Kapturczak N, Sikorski E, Voakes C, et al. An internal enhancer regulates heme-And cadmium-mediated induction of human heme oxygenase-1. Am J Physiol Renal Physiol. 2003;285(3):F515-F523.
17. Hollmen ME, Kyllonen LE, Inkinen KA, et al. Urine neutrophil gelatinaseassociated lipocalin is a marker of graft recovery after kidney transplantation. Kidney Int. 2011;79(1):89-98.
18. van Timmeren MM, Vaidya VS, van Ree RM, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation. 2007;84 (12):1625-1630.
19. Yarlagadda SG, Coca SG, Garg AX, et al.Marked variation in the definition and diagnosis of delayed graft function: A systematic review. Nephrol Dial Transplant. 2008;23(9):2995-3003.
20. Sharif A, Borrows R. Delayed graft function after kidney transplantation: The clinical perspective. Am J Kidney Dis. 2013;62(1):150-158.
21. Blydt-Hansen TD, Katori M, Lassman C, et al. Gene transfer-induced local heme oxygenase-1 overexpression protects rat kidney transplants from ischemia/reperfusion injury. J Am Soc Nephrol. 2003;14(3):745-754.
22. Lemos FB, Ijzermans JN, Zondervan PE, et al. Differential expression of heme oxygenase-1 and vascular endothelial growth factor in cadaveric and living donor kidneys after ischemia-reperfusion. J Am Soc Nephrol. 2003;14(12):3278-3287.
23. Tullius SG, Nieminen-Kelha M, Buelow R, et al. Inhibition of ischemia/reperfusion injury and chronic graft deterioration by a single-donor treatment with cobalt-protoporphyrin for the induction of heme oxygenase-1. Transplantation. 2002;74(5):591-598.
24. Ollinger R, Kogler P, Biebl M, et al. Protein levels of heme oxygenase-1 during reperfusion in human kidney transplants with delayed graft function. Clin Transplant. 2008;22(4):418-423.
25. Tsuchihashi S, Livhits M, Zhai Y, et al. Basal rather than induced heme oxygenase-1 levels are crucial in the antioxidant cytoprotection. J Immunol. 2006;177(7):4749-4757.
26. Tenhunen R, Tokola O, Linden IB. Haem arginate: A new stable haem compound. J Pharm Pharmacol. 1987;39(10):780-786.
27. Martinez F, Kamar N, Pallet N, et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: results of the Neo-PDGF Study. Am J Transplant. 2010;10(7):1695-1700.
28. Aydin Z, Mallat MJ, Schaapherder AF, et al. Randomized trial of shortcourse high-dose erythropoietin in donation after cardiac death kidney transplant recipients. Am J Transplant. 2012;12(7):1793-1800.
29. Fellstrom B, Holdaas H, Jardine AG, et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int. 2004;66(4):1549-1555.
30. Huang Y, Shan J, Wang C, et al. Can ischemic preconditioning alone really protect organs fromischemia reperfusion injury in transplantation. Transpl Immunol. 2009;20(3):127-131.